The consensus on rituximab administration in the treatment  of patients with rheumatoid arthritis

Jacek Szechliński; Piotr Głuszko; Eugeniusz Józef Kucharz; Włodzimierz Maśliński; Włodzimierz Samborski; Witold Tłustochowicz; Piotr Wiland

Abstract

3/2007 vol. 45

The consensus on rituximab administration in the treatment of patients with rheumatoid arthritis

Jacek Szechliński

,

Piotr Głuszko

,

Eugeniusz Józef Kucharz

,

Włodzimierz Maśliński

,

Włodzimierz Samborski

,

Witold Tłustochowicz

,

Piotr Wiland

Reumatologia 2007; 45, 3: 115–119

Online publish date: 2007/07/02

View full text

AMA

Szechliński J, Głuszko P, Kucharz E, et al. The consensus on rituximab administration in the treatment of patients with rheumatoid arthritis. Reumatologia/Rheumatology. 2007;45(3):115-119.

APA

Szechliński, J., Głuszko, P., Kucharz, E., Maśliński, W., Samborski, W., & Tłustochowicz, W. et al. (2007). The consensus on rituximab administration in the treatment of patients with rheumatoid arthritis. Reumatologia/Rheumatology, 45(3), 115-119.

Chicago

Szechliński, Jacek, Piotr Głuszko, Eugeniusz Józef Kucharz, Włodzimierz Maśliński, Włodzimierz Samborski, Witold Tłustochowicz, and Piotr Wiland. 2007. "The consensus on rituximab administration in the treatment of patients with rheumatoid arthritis". Reumatologia/Rheumatology 45 (3): 115-119.

Harvard

Szechliński, J., Głuszko, P., Kucharz, E., Maśliński, W., Samborski, W., Tłustochowicz, W., and Wiland, P. (2007). The consensus on rituximab administration in the treatment of patients with rheumatoid arthritis. Reumatologia/Rheumatology, 45(3), pp.115-119.

MLA

Szechliński, Jacek et al. "The consensus on rituximab administration in the treatment of patients with rheumatoid arthritis." Reumatologia/Rheumatology, vol. 45, no. 3, 2007, pp. 115-119.

Vancouver

Szechliński J, Głuszko P, Kucharz E, Maśliński W, Samborski W, Tłustochowicz W et al. The consensus on rituximab administration in the treatment of patients with rheumatoid arthritis. Reumatologia/Rheumatology. 2007;45(3):115-119.

Rituximab is a biologic B-cell targeted treatment in rheumatoid arthritis. A present consensus statement was formulated in order to determine indications and contraindications of using rituximab in rheumatoid arthritis. This statement was established based on data from randomized controlled trials on haematology and rheumatology. Rituximab in combination with methotrexate constitutes a major advance in the treatment of adult patients with rheumatoid arthritis who have had inadequate response or intolerance of disease modifying anti-rheumatic drugs (DMARDs) including one or more TNF-blocking agents.